microdosing glp-1 agonists vs. Standard Dosing: A Provider-Guided Comparison Microdosing GLP-1 for autoimmune conditions:
Description
People generally report mild to no pain with the injection
Ozempic (semaglutide) is a medication used to manage type 2 diabetes
Background Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM)
This analysis was part of the IMI-Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy (IMI-SOPHIA) project
These findings align with prior randomized trials and meta-analyses suggesting class-level cardiovascular benefit
